NCT06697938 Neoadjuvant Chemoradiotherapy Compared to Neoadjuvant Chemotherapy for Luminal-Type Locally Advanced Breast Cancer: A Clinical Study
| NCT ID | NCT06697938 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sichuan Cancer Hospital and Research Institute |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 148 participants |
| Start Date | 2024-11-18 |
| Primary Completion | 2027-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 148 participants in total. It began in 2024-11-18 with a primary completion date of 2027-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study focuses on preoperative treatment modalities for luminal-type locally advanced breast cancer. Based on modern precision radiotherapy technologies such as MRI-Linac, CyberKnife, and VMAT, it aims to compare the pCR rate, breast conserving surgery (BCS) rate, progression-free survival (PFS), and treatment-related side effects between preoperative neoadjuvant chemotherapy and preoperative neoadjuvant SBRT combined with chemotherapy in patients with this type of breast cancer. The goal is to provide new strategic options for the preoperative treatment of luminal-type locally advanced breast cancer.
Eligibility Criteria
Inclusion Criteria: 1. Pathologically confirmed invasive breast cancer ; 2. Breast MRI showing stages IIB to IIIC (2017 AJCC 8th edition staging); 3. Clinical staging confirmed by chest MRI and/or axillary ultrasound, as well as CT scans of the neck, abdomen, and pelvis, and bone scintigraphy, including T and N staging and assessment of distant metastasis; 4. Karnofsky performance score ≥80 or ECOG performance status of 0-1; 5. No history of allergies to doxorubicin, cyclophosphamide, paclitaxel/docetaxel; 6. No prior exposure to radiotherapy, chemotherapy, endocrine therapy, targeted therapy, or immunotherapy. Exclusion Criteria: 1. History of malignancy at other sites, excluding curable non-melanoma skin cancer and carcinoma in situ of the cervix; 2. Inability to complete MRI; 3. Inflammatory breast cancer; 4. Bilateral or multifocal primary tumors; 5. Active infection currently present; clinically evident heart disease; myocardial infarction or cerebrovascular accident within 6 months prior to enrollment.
Contact & Investigator
Qian Peng, Phd
PRINCIPAL INVESTIGATOR
Sichuan Cancer Hospital and Research Institute
Frequently Asked Questions
Who can join the NCT06697938 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06697938 currently recruiting?
Yes, NCT06697938 is actively recruiting participants. Contact the research team at pengqian@scszlyy.org.cn for enrollment information.
Where is the NCT06697938 trial being conducted?
This trial is being conducted at Chengdu, China.
Who is sponsoring the NCT06697938 clinical trial?
NCT06697938 is sponsored by Sichuan Cancer Hospital and Research Institute. The principal investigator is Qian Peng, Phd at Sichuan Cancer Hospital and Research Institute. The trial plans to enroll 148 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.